Performance Evaluation of IoT-based SpO2 Monitoring Systems for COVID-19 Patients

  • Trie Maya Kadarina Universitas Mercu Buana
  • Rinto Priambodo
Keywords: IoT; SpO2; Monitoring System; COVID-19


Internet of Things (IoT) applications can be used in healthcare services to monitor patients remotely. One implementation is that it is used to monitor COVID-19 patients. During the COVID-19 pandemic, people who are infected without symptoms must self-isolate so that the virus does not spread. Measurement of blood oxygen levels or SpO2 is one of the measurements that must be carried out in routine examination procedures for self-isolating patients for early detection of silent hypoxemia in COVID-19 patients. Previous research has developed an IoT-based health monitoring system with a Wireless Body Sensor Network (WBSN) and a gateway that can be used for data acquisition and transmission. The system uses a home pulse oximeter to measure SpO2 and heart rate and an Android application that functions as an IoT gateway to collect data from sensors and add location information before sending data to the server. The WBSN has been successfully integrated with two types of open source IoT platforms, namely ThingsBoard and Elasticsearch Logstash Kibana (ELK). However, it is necessary to carry out further studies on analytical and experimental performance tests of the two systems. Therefore, the purpose of this study is to develop a performance evaluation of the IoT-based SpO2 monitoring systems using the Thingsboard and ELK as IoT platforms. To evaluate the performace we ran the monitoring system on both platforms using pulse oximeter and Android device as IoT gateway with HTTP and MQTT as transport protocol for sending the data to the server. From this study we found that average time of message delivery in ELK compared to ThingsBoard using the same protocols was higher but stable.


Download data is not yet available.
How to Cite
Trie Maya Kadarina and R. Priambodo, “Performance Evaluation of IoT-based SpO2 Monitoring Systems for COVID-19 Patients”,, vol. 3, no. 2, pp. 64-71, Jul. 2021.